ELISpot Protocol: Cytokine-Secreting Cell Detection, Controls and Troubleshooting

ELISpot (enzyme-linked immunospot) is a highly sensitive cell-based immunoassay used to detect and count individual cells that secrete a defined protein, most commonly cytokines such as IFN-γ, IL-2, IL-4, IL-17 or TNF. Rather than measuring the bulk concentration of secreted protein in culture supernatant, ELISpot captures analyte close to the cell that released it. After the cells are removed, each localised secretion event is visualised as a spot on the membrane.

This makes ELISpot particularly useful for measuring rare antigen-specific T-cell or B-cell responses, vaccine responses, immune monitoring and functional cytokine secretion. The assay can detect low-frequency responding populations that may be difficult to resolve by bulk ELISA.

Use this protocol as a general starting framework. Capture and detection antibody concentrations, cell number, stimulus concentration and incubation time are analyte- and kit-dependent. If using a commercial ELISpot kit or validated antibody pair, follow the product-specific protocol in preference to general conditions below.

Principle of the ELISpot assay

ELISpot plates contain a protein-binding membrane, commonly PVDF. Capture antibody immobilised on the membrane binds the analyte as it is secreted by nearby cells. After the secretion period, cells are removed and the captured analyte is detected with a second antibody. Enzyme-labelled detection chemistry generates an insoluble coloured precipitate at the site of secretion. Each discrete spot is generally interpreted as one analyte-secreting cell, provided spots remain sufficiently separated and the assay is operating in its countable range.

Common ELISpot applications

• Quantifying antigen-specific T-cell responses.
• Measuring IFN-γ, IL-2, IL-4, IL-17 and other cytokine-secreting populations.
• Monitoring vaccine-induced cellular immunity.
• Assessing immune responses to peptides, proteins, pathogens or tumour antigens.
• Enumerating antibody-secreting B cells.
• Comparing functional immune responses between treatment groups.
• Detecting low-frequency secreting cells in PBMC preparations.

Equipment required

• 96-well ELISpot plate with PVDF or other validated membrane.
• Cell culture incubator, typically 37°C with 5% CO₂ for mammalian immune-cell assays.
• Multichannel pipette and sterile pipette tips.
• Cell counter or haemocytometer.
• Refrigerated centrifuge for cell preparation.
• Plate washer or careful manual washing setup.
• ELISpot reader or high-quality imaging system with validated counting software.

Reagents

• Capture antibody specific to the secreted analyte.
• Biotinylated or otherwise labelled detection antibody recognising a different epitope.
• Streptavidin–enzyme conjugate where using a biotinylated detection antibody.
• Substrate appropriate to the enzyme, for example AEC for HRP or BCIP/NBT for alkaline phosphatase.
• PBS and wash buffer.
• Blocking or cell culture medium validated for the assay.
• Viable cells such as PBMCs, purified T cells, B cells or another relevant cell type.
• Antigen, peptide pool, mitogen or experimental stimulus.
• Positive-control stimulus and unstimulated/vehicle control.

Before starting: experimental design

Choose the right cell number

The optimal number of cells per well depends on the expected frequency of responding cells. Too few cells can reduce sensitivity; too many can produce merged or saturated spots that cannot be counted reliably. For a new assay, test more than one cell input so at least one condition falls within the reader's countable range.

Include a positive-control stimulus

A strong positive control confirms cell viability, secretion competence and detection chemistry. The specific positive control should be appropriate to the cell type and analyte. A failed positive control makes a negative antigen-specific result difficult to interpret.

Use an unstimulated negative control

Background secretion varies between donors, cell preparations and cytokines. Unstimulated wells are required to estimate baseline spots and define antigen-specific responses.

Protect cell viability

ELISpot is a functional live-cell assay during the stimulation phase. Excessive sample handling, low viability, residual ethanol from PVDF pre-wetting or toxic buffer components can suppress responses or increase non-specific background.

Detailed ELISpot protocol

1. Prepare the membrane plate. If required by the plate manufacturer, briefly pre-wet the PVDF membrane using the validated alcohol-based procedure for that membrane. Immediately wash thoroughly with PBS or assay buffer so no residual alcohol remains before antibody coating or cell addition. Do not assume every ELISpot membrane requires identical pre-wetting conditions.
2. Coat with capture antibody. Dilute the capture antibody in PBS or the specified coating buffer. Add sufficient volume to cover the membrane uniformly. For a custom assay, establish the capture-antibody concentration by titration against positive and negative controls rather than transferring a nominal concentration from another antibody pair.
3. Incubate the coating step. Cover the plate and incubate overnight at 4°C or according to the validated antibody-pair protocol.
4. Wash the plate. Remove the coating solution and wash with sterile PBS to remove unbound antibody.
5. Block the membrane. Add the recommended blocking or culture medium and incubate long enough to reduce non-specific adsorption. Keep the membrane wet from this point onward until the final development stage.
6. Prepare cells. Count viable cells and adjust to the required concentration. For cryopreserved PBMCs, allow an appropriate recovery/rest period when validated for the assay. Remove debris and dead cells where necessary.
7. Add cells. Dispense equal cell numbers into replicate wells. If optimising, plate a short dilution series of cell numbers.
8. Add antigen or stimulus. Add antigen, peptide pool, mitogen, vehicle control or other stimulus at the validated concentration. Include unstimulated wells and a positive-control stimulus.
9. Incubate to allow secretion. Incubate under suitable cell culture conditions. Many cytokine ELISpot assays use an overnight or 12–24 hour stimulation, but the correct duration depends on the analyte, cell type and stimulation mechanism.
10. Remove cells. Discard the cell suspension and wash the wells thoroughly using the recommended wash buffer. The objective is to remove cells and unbound material without damaging the membrane.
11. Add detection antibody. Apply the biotinylated or labelled detection antibody at the validated concentration and incubate as specified by the antibody pair or kit.
12. Wash thoroughly. Insufficient washing increases diffuse background and poorly defined spots.
13. Add enzyme conjugate. Where using biotin detection, add streptavidin-HRP or streptavidin-alkaline phosphatase at the recommended dilution and incubate.
14. Wash again. Remove excess enzyme conjugate completely before substrate development.
15. Add substrate. Add a compatible precipitating substrate. Monitor development; spots should become clearly visible without allowing the whole membrane to darken.
16. Stop development. Stop the reaction according to the substrate protocol, commonly by thorough washing with water.
17. Dry the plate. Allow the membrane to dry completely before automated spot counting if required by the reader.
18. Count spots. Analyse with an ELISpot reader using consistent detection settings. Inspect representative wells manually to ensure software is distinguishing true spots from artefacts.

Controls for a robust ELISpot experiment

• Unstimulated/vehicle control: measures baseline spontaneous secretion.
• Positive-control stimulus: confirms that the cells can respond and secrete the analyte.
• Cell-free well: helps reveal reagent or membrane background.
• Detection control: useful during assay development to verify the detection system independently.
• Replicate wells: duplicate or triplicate wells help distinguish biological signal from plating variability.
• Cell-count titration: especially useful during optimisation to identify the linear/countable range.

ELISpot versus ELISA

ELISA measures the total concentration of analyte accumulated in a sample or supernatant. ELISpot measures the frequency of individual cells that secreted the analyte during the assay period. Two cultures can therefore have similar bulk cytokine concentration but different numbers of responding cells, or the same number of responding cells with different per-cell secretion intensity.

ELISpot versus intracellular cytokine flow cytometry

ELISpot is highly sensitive for secreted responses and can detect rare responding populations without complex flow cytometry panels. Intracellular cytokine staining, however, can combine cytokine detection with phenotype markers to identify which subpopulation produced the cytokine. The methods are complementary rather than interchangeable.

Data analysis and reporting

• Report spots as spot-forming units (SFU) per stated number of input cells, for example per 10⁶ PBMCs.
• Subtract or otherwise account for background only according to a pre-defined analysis rule.
• Report replicate variability and the criterion used to define a positive response.
• Do not compare spot counts across experiments without considering differences in cell number, viability, incubation time, plate lot, antibody pair and reader settings.
• Inspect spot morphology. Very large diffuse spots, membrane staining or merged clusters can indicate overdevelopment, excessive cell number or non-specific background.

Optimisation factors that most affect ELISpot performance

Cell number

High responder frequency can overload the membrane. Low responder frequency may require more cells, replicate wells or a more sensitive antibody pair.

Stimulus concentration and duration

Too little stimulus may under-activate cells; too much can cause toxicity or non-specific activation. Optimise around the biology of the antigen and the analyte kinetics.

Capture and detection antibody pair

The two antibodies must bind distinct compatible epitopes. A pair that performs well in sandwich ELISA may be a useful starting point but should still be validated for ELISpot.

Washing

Incomplete removal of cells or detection reagents can create background and irregular spot morphology. Avoid touching or scratching the membrane during manual washing.

Substrate development

Overdevelopment can merge spots and increase membrane background. Use a consistent development window and stop the reaction before the background becomes strong.

Warnings and common analytical traps

• Do not assume every visible spot represents exactly one cell when wells are crowded. Closely spaced secretion zones can merge.
• Do not compare raw spot counts from different cell inputs. Report a defined denominator such as SFU per 10⁶ viable cells.
• Do not ignore negative-control background. High spontaneous secretion can make an apparently strong stimulated response uninterpretable.
• Do not let plate-reader settings become a hidden variable. Fix counting rules before comparing groups and visually audit automated counts.
• Do not treat technical replicate wells as independent biological replicates.

Limitations

• A single spot is generally treated as a secreting cell, but spot size and intensity can vary with secretion rate and diffusion.
• Closely adjacent secreting cells can produce merged spots, particularly at high cell density.
• The assay usually provides limited phenotype information unless cells are purified or combined with complementary techniques.
• Cell viability and pre-analytical handling have a major influence on response.
• Different readers and analysis settings can produce different spot counts from the same plate.
• Results should not be compared across laboratories without harmonised protocols and analysis criteria.

Troubleshooting

Frequently asked questions

How many cells should I plate per ELISpot well?

There is no universal value. Choose the number according to the expected responder frequency and optimise with a short cell dilution series. The ideal well has enough spots for robust counting without spot overlap.

How long should cells be stimulated?

Many cytokine assays use 12–24 hours, but secretion kinetics differ by analyte and stimulus. Use validated kit guidance or optimise a time course.

Why are there spots in my negative control?

Some cells secrete cytokines spontaneously, particularly after difficult isolation, thawing or activation. High negative-control counts can also reflect non-specific stimulation or assay background.

Can ELISpot be used with frozen PBMCs?

Yes, but thawing quality, viability and recovery conditions strongly affect results. Apply the same thawing/rest procedure across all samples and confirm function with a positive control.

Does every spot equal exactly one cell?

That is the operating assumption when spots are well separated, but overlapping secretion zones and very strong secretors can complicate one-spot/one-cell interpretation.

References and journal sources

1. Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods. 1988;110:29–36. doi:10.1016/0022-1759(88)90079-8.
2. Janetzki S et al. Results and harmonization guidelines from two large-scale international ELISPOT proficiency panels. Cancer Immunol Immunother. 2008.
3. Guidelines for the automated evaluation of ELISPOT assays. 2015. PMID:26110715.
4. Harmonization and qualification of an IFN-γ ELISPOT assay to measure influenza-specific cell-mediated immunity within the FLUCOP consortium. 2022. PMID:36159843.
5. Proficiency tests evaluating harmonized influenza-specific ICS and IFN-γ ELISPOT protocols. J Immunol Methods. 2023;113584. doi:10.1016/j.jim.2023.113584.

Relevant ABMIUM products

These are catalogue examples for common human cytokine ELISpot workflows. Confirm analyte, species, sample type and kit instructions before use.

• Human IFN-γ (Interferon Gamma) ELISPOT Kit — relevant to T-cell and vaccine-response workflows measuring IFN-γ secretion.
• Human IL-2 ELISPOT Kit — for human IL-2-secreting cell enumeration.
• Human IL-17A ELISPOT Kit — for human IL-17A-secreting cell workflows.
• Human IL-10 ELISPOT Kit — for human IL-10-secreting cell workflows.

Explore more with ABMIUM

Building an ELISpot experiment? Explore ELISpot kits, compare cytokine antibodies, or use Find your MATCH if you need a target/species-specific recommendation. For related workflows, continue to the Flow Cytometry Protocol and Sandwich ELISA Protocol.